OCT 31, 2018 8:00 AM PDT

Researchers identify a protein marker that induces dormancy in metastatic breast cancer

WRITTEN BY: Heba El-wassef

Researchers at the Mount Sinai hospital identified for the first time, a protein marker that could indicate whether breast cancer will further metastasize or remain in a dormant state, according to a clinical study published in Breast Cancer Research this month.

Breast cancer patients can relapse and die from the disease years after their primary treatment, which indicated that some of the tumor cells, called disseminated tumor cells (DTCs), remain in a dormant state with no or slow proliferation, with the ability to progress and proliferate later. However, studies also showed that 60% of DTC-positive patients did not relapse. Therefore, there was a need for more studies to understand the biology behind this dormancy behavior.

Disseminated tumor cells are cancer cells that have left the primary tumor and survived in the circulation to land in a distant organ. Credit:https://www.kennethjpienta.com

This new research showed that when DTCs metastasize from their original tumor into the patients bone marrow, with no or a small amount of the protein receptor NR2F1, the patient relapse and soon dies. Patients who had a higher concentration of NR2F1 in their DTCs did not develop metastasis and survived longer. The higher concentration of NR2F1 induced the dormancy state, deactivating cancer cells and preventing metastasis.

These findings suggest that NR2F1 concentration can be used as an indicator of whether there is a possibility for tumor metastasis requiring additional treatments, or if the cancer cells will remain dormant which will save the patient from unnecessary treatments.

This research was a collaboration between Mount Sinai researchers and physicians in Oslo, Norway, where bone marrow tests called aspirates, which are not used in the US, are used to monitor patients.

“Improved techniques to assess the population of patients with residual disease and their dormant or reactivating state will be key to identifying the risk of future metastasis despite undergoing standard treatment. This opens the way for testing new treatments that prevent metastasis by inducing dormancy or eradicating the dormant disseminated cancer cells that have not yet initiated metastatic growth,” said lead researcher, Julio Aguirre-Ghiso, PhD, Director of Solid Tumor and Metastasis Research, Director of Head and Neck Cancer Basic Research, and Professor of Oncological Sciences, Otolaryngology, and Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Earlier studies showed that higher concentrations of NR2F1 are induced in response to androgen deprivation treatment, an anti-hormone treatment used in prostate cancer, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai will soon start a new clinical study testing the ability of two drugs to induce dormancy through upregulation of NR2F1 in prostate cancer patients.

Source: Sciencedaily via Mount Sinai

About the Author
BS in Biochemistry
A master student in Biochemistry and Molecular biology with experience in Education and Research. I am passionate about scientific research and passing my knowledge to others to help them learn about the latest in science by teaching, writing and volunteering in scientific events.
You May Also Like
AUG 08, 2022
Immunology
Controls and Calibrators for Measurement Assurance in Flow Cytometry: New Applications and New Requirements
AUG 08, 2022
Controls and Calibrators for Measurement Assurance in Flow Cytometry: New Applications and New Requirements
One of the primary objectives for the application of flow cytometry in any testing environment should be measurement ass ...
AUG 29, 2022
Cancer
Could Robotic Surgery Provide Better Care for Patients with Kidney Cancer?
AUG 29, 2022
Could Robotic Surgery Provide Better Care for Patients with Kidney Cancer?
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for about 90% of kidney cancer incidence ...
SEP 14, 2022
Health & Medicine
Researchers Suggest Updating Alcohol Warning Labels
SEP 14, 2022
Researchers Suggest Updating Alcohol Warning Labels
Current warning labels that appear on alcohol products in the US are outdated, vague, and not helpful to people who want ...
OCT 06, 2022
Chemistry & Physics
2022 Nobel Prize in Chemistry
OCT 06, 2022
2022 Nobel Prize in Chemistry
It’s that time of year again! Three scientists, Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless, were a ...
NOV 03, 2022
Cancer
Uterine Cancer Linked to Hair Straightening Products
NOV 03, 2022
Uterine Cancer Linked to Hair Straightening Products
While uterine cancer represents only 3% of all cancer diagnoses in the United States, it remains the most common female ...
NOV 29, 2022
Cell & Molecular Biology
How a Master Regulator May be Working to Protect Cancer
NOV 29, 2022
How a Master Regulator May be Working to Protect Cancer
Scientists have now discovered yet another way that MYC proteins can promote cancer. MYC has been called a master regula ...
Loading Comments...